On November 17, Luye Pharmaceutical Group announced that LY03021, the next-generation central nervous system drug under development independently developed by the company, has obtained permission from the US Food and Drug Administration to conduct clinical trials and is intended to be used to treat depression.

Zhitongcaijing · 3d ago
On November 17, Luye Pharmaceutical Group announced that LY03021, the next-generation central nervous system drug under development independently developed by the company, has obtained permission from the US Food and Drug Administration to conduct clinical trials and is intended to be used to treat depression.